{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective from the specified list.", "method": "llm_batch", "batch_id": "batch_1_11412", "batch_size": 260, "batch_pos": 140, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment uses factual language without high-potency verbs or metaphors.", "method": "llm_batch", "batch_id": "batch_2_17048", "batch_size": 260, "batch_pos": 124, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "Factual statement without moderate verb + scale/impact.", "method": "llm_batch", "batch_id": "batch_3_16328", "batch_size": 260, "batch_pos": 75, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_16436", "batch_size": 260, "batch_pos": 65, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports the history of research, which is factual information.", "method": "llm_batch", "batch_id": "batch_5_6580", "batch_size": 260, "batch_pos": 64, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_1544", "batch_size": 260, "batch_pos": 40, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "No bare negation detected.", "method": "llm_batch", "batch_id": "batch_7_17832", "batch_size": 260, "batch_pos": 26, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "no", "rationale": "The segment describes historical research focus, not a capability or preparedness measure.", "method": "llm_batch", "batch_id": "batch_8_15008", "batch_size": 260, "batch_pos": 153, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 9, "answer": "no", "rationale": "The segment reports vaccine research history, not prices or numerical metrics.", "method": "llm_batch", "batch_id": "batch_9_17696", "batch_size": 260, "batch_pos": 31, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 10, "answer": "no", "rationale": "The segment provides background information, not speculation about future relief.", "method": "llm_batch", "batch_id": "batch_10_15320", "batch_size": 260, "batch_pos": 152, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 11, "answer": "no", "rationale": "Attributed statement reports facts, no framing language.", "method": "llm_batch", "batch_id": "batch_11_8588", "batch_size": 260, "batch_pos": 147, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 12, "answer": "yes", "rationale": "No explicit Alarmist or Reassuring framing cues; facts presented neutrally.", "method": "llm_batch", "batch_id": "batch_12_13428", "batch_size": 260, "batch_pos": 147, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
